• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Five-year survival analysis and prognostic factors in patients operated on for non-small cell lung cancer with N2 disease.N2期非小细胞肺癌手术患者的五年生存分析及预后因素
J Thorac Dis. 2018 Jun;10(6):3180-3186. doi: 10.21037/jtd.2018.05.173.
2
The impact of multiple metastatic nodal stations on survival in patients with resectable N1 and N2 nonsmall-cell lung cancer.多个转移淋巴结站对可切除的N1和N2期非小细胞肺癌患者生存的影响。
Ann Thorac Surg. 2008 Oct;86(4):1092-7. doi: 10.1016/j.athoracsur.2008.06.056.
3
Lobectomy does not confer survival advantage over segmentectomy for non-small cell lung cancer with unsuspected nodal disease.肺叶切除术并不比节段切除术更能为伴有隐匿性淋巴结疾病的非小细胞肺癌患者带来生存优势。
J Thorac Cardiovasc Surg. 2020 Jun;159(6):2469-2483.e4. doi: 10.1016/j.jtcvs.2019.10.165. Epub 2019 Nov 21.
4
Ratio between maximum standardized uptake value of N1 lymph nodes and tumor predicts N2 disease in patients with non-small cell lung cancer in 18F-FDG PET-CT scan.18F-FDG PET-CT扫描中,非小细胞肺癌患者N1淋巴结最大标准化摄取值与肿瘤的比值可预测N2期疾病。
Rev Esp Med Nucl Imagen Mol. 2016 May-Jun;35(3):159-64. doi: 10.1016/j.remn.2015.08.004. Epub 2015 Oct 26.
5
Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.基线可切除 IIIA-N2 期非小细胞肺癌的外科多模态治疗。纵隔淋巴结受累程度及对生存的影响。
Eur J Cardiothorac Surg. 2009 Sep;36(3):433-9. doi: 10.1016/j.ejcts.2009.04.013. Epub 2009 Jun 6.
6
Skip mediastinal nodal metastases in the IIIa/N2 non-small cell lung cancer.Ⅲa期/N2期非小细胞肺癌纵隔淋巴结转移的漏诊情况
J Thorac Oncol. 2007 Nov;2(11):1018-21. doi: 10.1097/JTO.0b013e318158d471.
7
Prognostic factors in surgically resected N2 non-small cell lung cancer: the importance of patterns of mediastinal lymph nodes metastases.手术切除的N2期非小细胞肺癌的预后因素:纵隔淋巴结转移模式的重要性
Eur J Cardiothorac Surg. 2005 Jul;28(1):33-8. doi: 10.1016/j.ejcts.2005.03.016.
8
Survival benefit of skip metastases in surgically resected N2 non-small cell lung cancer: A multicenter observational study of a large cohort of the Chinese patients.手术切除的 N2 期非小细胞肺癌中跳跃性转移的生存获益:一项对中国患者大队列进行的多中心观察性研究。
Eur J Surg Oncol. 2020 Oct;46(10 Pt A):1874-1881. doi: 10.1016/j.ejso.2019.12.015. Epub 2019 Dec 18.
9
[Clinical analysis of skip N2 metastases in stage IIIA non-small cell lung cancer].[ⅢA期非小细胞肺癌跳跃式N2转移的临床分析]
Ai Zheng. 2009 Jul;28(7):725-9. doi: 10.5732/cjc.008.10849.
10
The impact of superior mediastinal lymph node metastases on prognosis in non-small cell lung cancer located in the right middle lobe.右上中叶非小细胞肺癌纵隔淋巴结转移对预后的影响
J Thorac Oncol. 2011 Mar;6(3):494-9. doi: 10.1097/JTO.0b013e31820b8891.

引用本文的文献

1
Prognostic Value of Lymph Node Ratio (LNR) in Patients with Postoperative N2 Feature in Non-Small Cell Lung Cancer (NSCLC).淋巴结比率(LNR)在非小细胞肺癌(NSCLC)术后N2特征患者中的预后价值
J Clin Med. 2024 Aug 5;13(15):4570. doi: 10.3390/jcm13154570.
2
Tumor size as a predictor for prognosis of patients with surgical IIIA-N2 non-small cell lung cancer after surgery.肿瘤大小作为手术治疗的IIIA-N2期非小细胞肺癌患者术后预后的预测指标。
J Thorac Dis. 2021 Jul;13(7):4114-4124. doi: 10.21037/jtd-21-428.
3
Nodal Involvement Pattern in Clinical Stage IA Non-Small Cell Lung Cancer According to Tumor Location.根据肿瘤位置分析临床IA期非小细胞肺癌的淋巴结受累模式
Cancer Manag Res. 2020 Aug 26;12:7875-7880. doi: 10.2147/CMAR.S262623. eCollection 2020.
4
Up-Regulation of FSTL3, Regulated by lncRNA DSCAM-AS1/miR-122-5p Axis, Promotes Proliferation and Migration of Non-Small Cell Lung Cancer Cells.由lncRNA DSCAM-AS1/miR-122-5p轴调控的FSTL3上调促进非小细胞肺癌细胞的增殖和迁移。
Onco Targets Ther. 2020 Apr 1;13:2725-2738. doi: 10.2147/OTT.S236359. eCollection 2020.
5
Risk analyses of N2 lymph-node metastases in patients with T1 non-small cell lung cancer: a multi-center real-world observational study in China.中国多中心真实世界观察性研究:T1 期非小细胞肺癌患者 N2 淋巴结转移的风险分析。
J Cancer Res Clin Oncol. 2019 Nov;145(11):2771-2777. doi: 10.1007/s00432-019-03006-x. Epub 2019 Aug 19.

本文引用的文献

1
Lung cancer epidemiology: contemporary and future challenges worldwide.肺癌流行病学:全球当代和未来的挑战。
Ann Transl Med. 2016 Apr;4(8):150. doi: 10.21037/atm.2016.03.11.
2
Lymph node metastasis according to primary tumor location in T1 and T2 stage non-small cell lung cancer patients.T1和T2期非小细胞肺癌患者中根据原发肿瘤位置的淋巴结转移情况
Thorac Cancer. 2016 Apr 26;7(3):304-9. doi: 10.1111/1759-7714.12328. Epub 2016 Jan 4.
3
Clinical analysis of sixty-four patients with T1aN2M0 stage non-small cell lung cancer who had undergone resection.64 例 T1aN2M0 期非小细胞肺癌患者切除术的临床分析。
Thorac Cancer. 2016 Mar;7(2):215-21. doi: 10.1111/1759-7714.12314. Epub 2015 Oct 6.
4
Adjuvant chemotherapy plus radiotherapy is superior to chemotherapy following surgical treatment of stage IIIA N2 non-small-cell lung cancer.对于IIIA期N2非小细胞肺癌患者,手术治疗后辅助化疗加放疗优于单纯化疗。
Onco Targets Ther. 2016 Feb 24;9:921-8. doi: 10.2147/OTT.S95517. eCollection 2016.
5
Candidates for Intensive Local Treatment in cIIIA-N2 Non-Small Cell Lung Cancer: Deciphering the Heterogeneity.cIIIA-N2 期非小细胞肺癌强化局部治疗的候选人群:解析异质性。
Int J Radiat Oncol Biol Phys. 2016 Jan 1;94(1):155-162. doi: 10.1016/j.ijrobp.2015.09.026. Epub 2015 Sep 26.
6
Lung adenocarcinoma: Are skip N2 metastases different from non-skip?肺腺癌:跳跃性 N2 转移与非跳跃性转移有何不同?
J Thorac Cardiovasc Surg. 2015 Oct;150(4):790-5. doi: 10.1016/j.jtcvs.2015.03.067. Epub 2015 Jul 6.
7
Risk factors for recurrence after complete resection of pathological stage N2 non-small cell lung cancer.病理 N2 期非小细胞肺癌完全切除术后复发的危险因素。
Thorac Cancer. 2015 Mar;6(2):166-71. doi: 10.1111/1759-7714.12159. Epub 2015 Mar 2.
8
Significant prognostic factors for completely resected pN2 non-small cell lung cancer without neoadjuvant therapy.未接受新辅助治疗的完全切除的pN2期非小细胞肺癌的显著预后因素。
Ann Thorac Cardiovasc Surg. 2015;21(4):345-53. doi: 10.5761/atcs.oa.14-00262. Epub 2015 Feb 16.
9
Prognostic Factors for Surgically Resected N2 Non-small Cell Lung Cancer.手术切除的N2期非小细胞肺癌的预后因素
Ann Thorac Cardiovasc Surg. 2015;21(3):217-22. doi: 10.5761/atcs.oa.14-00218. Epub 2015 Jan 26.
10
Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer.小尺寸非小细胞肺癌患者淋巴结转移的预测风险因素
J Thorac Dis. 2014 Dec;6(12):1697-703. doi: 10.3978/j.issn.2072-1439.2014.11.05.

N2期非小细胞肺癌手术患者的五年生存分析及预后因素

Five-year survival analysis and prognostic factors in patients operated on for non-small cell lung cancer with N2 disease.

作者信息

Łochowski Mariusz, Łochowska Barbara, Rębowski Marek, Brzeziński Daniel, Cieślik-Wolski Bartosz, Kozak Józef

机构信息

Department of Thoracic Surgery, Memorial Copernicus Hospital, Medical University of Lodz, Lodz, Poland.

Department of Chemotherapy, Memorial Copernicus Hospital, Medical University of Lodz, Lodz, Poland.

出版信息

J Thorac Dis. 2018 Jun;10(6):3180-3186. doi: 10.21037/jtd.2018.05.173.

DOI:10.21037/jtd.2018.05.173
PMID:30069313
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6051815/
Abstract

BACKGROUND

The aim of the study is to analyse 5-year survival and prognostic factors in patients operated due to lung cancer with postoperatively confirmed metastases to N2 group nodes.

METHODS

In the years 2007-2015, 1,148 patients with lung cancer were treated surgically. A postoperative histopathological study confirmed N2 feature in 150 patients. One hundred and ten patients, in whom a 5-year survival analysis was possible to perform, were included in such analysis. The patients underwent the following procedures: pneumonectomy, 31 patients; lobectomy, 61; bilobectomy, 10; and wedge resection, 8. All patients were subjected to supplementary treatment after the surgery.

RESULTS

Five-year survival was achieved in 23 patients (21%). The patients' survival did not depend on the type of surgery, type of tumour, its location or presence of metastases in N1 nodes (P=0.82, P=0.51, P=0.36 and P=0.23, respectively). A statistically significant correlation was observed (P=0.01) between the 5-year survival of a patient and the occurrence of metastases only in one group of lymph nodes of the N2 feature (22 patients, 20%). Involvement of three or more mediastinal nodal groups resulted in survival shorter than 5-year.

CONCLUSIONS

(I) In patients with the N2 feature, the type of performed surgery, type of tumour and the occurrence of metastases in the lymph nodes of the lung hilum do not affect 5-year survival; (II) involvement of only one nodal group allows to achieve 5-year survival in 20% of patients; (III) involvement of three and more nodal groups with the N2 feature results in decreased 5-year survival.

摘要

背景

本研究旨在分析因肺癌手术且术后病理证实有N2组淋巴结转移患者的5年生存率及预后因素。

方法

2007年至2015年期间,1148例肺癌患者接受了手术治疗。术后组织病理学研究证实150例患者有N2特征。110例患者纳入5年生存分析。这些患者接受了以下手术:全肺切除术31例;肺叶切除术61例;双肺叶切除术10例;楔形切除术8例。所有患者术后均接受辅助治疗。

结果

23例患者(21%)实现了5年生存。患者的生存不取决于手术类型、肿瘤类型、肿瘤位置或N1组淋巴结有无转移(P值分别为0.82、0.51、0.36和0.23)。观察到患者的5年生存与仅在一组具有N2特征的淋巴结中发生转移之间存在显著统计学相关性(P = 0.01)(22例患者,20%)。三个或更多纵隔淋巴结组受累导致生存期短于5年。

结论

(I)对于具有N2特征的患者,所施行的手术类型、肿瘤类型及肺门淋巴结转移情况不影响5年生存率;(II)仅一组淋巴结受累使20%的患者实现5年生存;(III)三个及更多具有N2特征的淋巴结组受累导致5年生存率降低。